sftd
Neupro® (rotigotine transdermal system): First FDA-Approved Parkinson's Disease Patch
Filed in archive Treatment by Gloria Gamat on May 10, 2007
Neupro® (rotigotine transdermal system): First FDA-Approved Parkinson's Disease Patch
The first patch for Parkinson's disease has recently been approved by the USFDA: Neupro® (rotigotine transdermal system).

A product of Schwarz Bioscience (U.S. subsidiary of Schwarz Pharma AG), Neupro works by delivering the drug rotigotine (a dopamine agonist) continuously through the skin (transdermal) using a silicone-based patch that is replaced every 24 hours.

[A dopamine agonist works by activating dopamine receptors in the body, mimicking the effect of the neurotransmitter dopamine.]

Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease - belongs to a group of conditions called motor system disorders that is a result of the loss of dopamine-producing brain cells.

Read the full report from Schwarz Pharma and FDA.



Permalink: Neupro® (rotigotine transdermal system): First FDA-Approved Parkinson's Disease Patch
Tags: Parkinsons  disease  patch 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/68463
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Neupro® (rotigotine transdermal system): First FDA-Approved Parkinson's Disease Patch:

  • Currently 6.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 6.00 out of 2 vote(s) cast.
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!